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Abstract
Fasudil is a clinically approved Rho-associated protein kinase (ROCK) inhibitor that has been
used widely to treat cerebral consequences of subarachnoid haemorrhage. It is known to have
a positive effect on animal models of neurological disorders including Parkinson’s disease and
stroke. However, its cellular effect on progenitor populations and differentiation is not clearly
understood. While recent studies suggest that fasudil promotes the mobilization of neural stem
cells (NSCs) from the subventricular zone in vivo and promotes the differentiation of the C17.2
cerebellar neuroprogenitor line in vitro, it is unclear whether fasudil is involved in the
differentiation of primary NSCs.
Here, we tested the effect of fasudil on mouse NSCs in vitro, and observed increased
gliogenesis in NSCs derived from lateral ventricles. Upon treatment, fasudil promoted
characteristics of neurogenesis including phenotypic changes in neural outgrowth and
interkinetic nuclear-like movements as an immediate response, while Sox2 expression was
maintained and GFAP expression increased. Moreover, the gliogenic response to fasudil
medium was observed in both early postnatal and adult NSC cultures.
Taken together, our results show that fasudil promotes the differentiation of NSCs into
astroglial lineage, suggesting that it could be used to develop novel vitro gliogenesis models
and regulate differentiation for neural repair.
Highlights
• Primary mouse neural stem cells are fasudil responsive
• Exposure to Fasudil containing medium differentiates neural stem cells to a glial
phenotype.
• Fasudil treatment can be used in in vitro to model gliogenesis
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1. Introduction
Fasudil is a ROCK inhibitor that has been shown to alleviate symptoms from a range of CNS disorders
including subarachnoid haemorrhage, spinal cord injuries, cerebral stroke, Parkinson’s disease,
neuropathic pain and epilepsy (Chen, et al., 2013, Nakamura, et al., 2013, Satoh, et al., 2012, Hara, et
al., 2000, Baba, et al., 2010, Impellizzeri, et al., 2012, Wang, et al., 2012, Mueller, et al., 2005, Shibuya,
et al., 1992, Villar-Cheda, et al., 2012, Boyce-Rustay, et al., 2010, Inan, et al., 2008). Although other
ROCK inhibitors including C3 transferase and Y27632 have shown similar neurogenic effects on
animal models in vivo and in vitro, fasudil is the only clinically approved ROCK inhibitor currently in
use for patients suffering from CNS disorders (Jia, et al., 2016, Gu, et al., 2013).
Accumulation of Rho-associated protein kinase (ROCK) has been involved in a variety of neuronal
functions including inhibition of axonal regeneration, inhibition of neuronal differentiation and
proliferation of tumour cells (Chen, et al., 2013, Liu, et al., 2015, Compagnucci, et al., 2016, Ying, et
al., 2006). ROCK is a direct downstream effector of Rho, a member of the Rho-GTPases belonging to
the Ras superfamily (Liu, et al., 2015). There are two isoforms of ROCK – ROCK1 and ROCK2, of
which the latter is mainly expressed in the central nervous system. Myelin-associated inhibitory factors
such as myelin associated glycoprotein, oligodendrocyte myelin glycoprotein and Nogo can activate
the Rho-ROCK signalling pathway by binding to the Nogo receptor/Lingo-1/p75 receptor complex
present in the cell membrane (Liu, et al., 2015). Activated ROCK can then phosphorylate the myosin
light chain which leads to a series of events that causes neurite retraction and collapse of the growth
cone in the central nervous system (Liu, et al., 2015). The result is a lack of nerve growth, neural support
and axon regeneration. Therefore, inhibitors for Rho-ROCK pathway are being targeted for their
potential to treat neurological disorders (Chen, et al., 2013).
An in vivo study has shown that intra peritoneal administration of fasudil in a hypoxia/reoxygenation
mouse model can mobilise endogenous progenitors from the SVZ, suggesting that NSCs may be
fasudil-responsive (Ding, et al., 2010). Moreover, a recent study reported that fasudil could differentiate
the cerebellum-derived C17.2 neural cell line into neurons and glia in vitro. However the cellular effects
of this drug on neuroprogenitor cell populations remain unclear and there has been no study on the
response to fasudil in primary NSC cultures in vitro. Here, we analysed the effect of fasudil on primary
NSC culture and differentiation in vitro using cells isolated from the lateral ventricles of early postnatal
and adult mouse brain tissue.
2. Methods
All reagents used were purchased from Thermofisher (UK) unless otherwise stated.
2.1.Cell culture
For primary NSC isolation, lateral ventricle tissues from postnatal day 21 and adult mice brain were
isolated from lateral ventricle tissue, which was carefully dissected from coronal sections immersed in
PBS, transferred to a new dish to be briefly minced, and then transferred to a conical tube containing
Accumax (Sigma-Aldrich, UK) for 30 minutes at 37°C, with mild agitation every ten minutes. The
digested tissues were then washed with PBS and centrifuged at 200G for 5 minutes. The cell pellet was
re-suspended in NSC medium (made from DMEM F12/Neurobasal (1:1) medium containing 0.5%
Penicillin/Streptomycin (P/S) and 0.01% heparin, with B27 and N2 supplements, and added growth
factors bFGF and EGF (20ng/µl)). The cells were split using Accutase (Sigma-Aldrich, UK) and used
within 10 passages. For differentiation, postnatal NSCs were seeded on 0.1% gelatin coated coverslips
at 50,000 cells/ml (Adult LV-NSCs were seeded on Geltrex to reduce cell loss during immunostaining
washes). Upon reaching confluency, the medium was changed to differentiation medium (identical to
NSC medium but without growth factors), supplemented with 0.5% FCS, with or without 100µM
Fasudil (FAS, Tocris) as indicated. For neuronal differentiation, the differentiation medium without
Fasudil was supplemented with the retinoic acid analogue 1µM EC23 (Tocris) and 10ng/µl BDNF
(Source Bioscience) which was referred to as retinoid-based medium (RET).
C17.2 immortalised mouse cerebellar cells were cultured in DMEM high glucose medium
supplemented with 10% FCS and 0.5% P/S. This cell line was used as a positive control for fasudil
mediated neuronal differentiation in vitro (Chen, et al., 2015). For differentiation, C17.2 cells were
seeded onto coverslips placed at 40,000 cells/ml. After 24 hours, the medium was refreshed and
supplemented with 100µM FAS.
2.2.Neurite Outgrowth Analysis
Images of undifferentiated and FAS-treated cultures were captured using Nikon microscope and images
processed using ImageJ software (www.imagej.nih.gov/ij/). Images were captured from 3 independent
biological replicates, and from each replicate 3 image sections were selected for neurite outgrowth
measurements (technical replicates). Only the neurite lengths longer than the diameter of the cell body
were considered for analysis. Total neurite length was normalised to the number of cells visualised in
each image.
2.3.Immunohistochemistry
Cells were fixed in 4% ice-cold paraformaldehyde (PFA), washed with PBS, then incubated in 0.1%
Triton-X (Sigma-Aldrich), followed by a PBS wash. Samples were then washed briefly in PBT (PBS +
0.1% Tween20 (Sigma-Aldrich)) and blocked using 5% goat serum (Sigma-Aldrich) in PBS. Samples
were incubated overnight in primary antibodies diluted in blocking solution, using the following
antibody dilutions: Nestin (mouse monoclonal; 1:50; Dako), Sox2 (rabbit polyclonal; 1:500; EMD
Millipore), βIII-Tubulin (rabbit polyclonal; 1:1000; Abcam), GFAP (rabbit polyclonal; 1:250; Dako), 
S100b (1:200; Dako) and DCX (1:500; Cell Signalling). Samples were then briefly washed in PBT and
incubated for 1 hour in secondary antibodies diluted in blocking solution, with the following dilutions:
Alexa Fluor 488-conjugated goat anti-mouse (1:250), Alexa Fluor 488-conjugated goat anti-rabbit
(1:250), Alexa Fluor 594-conjugated goat anti-rabbit solution (1:20), Alexa Fluor 647-conjugated goat
anti-rabbit (1:250) followed by brief PBT wash. Samples were mounted using DAPI-containing
Vectashield mounting solution (Vector Laboratories, UK) and imaged with a Nikon Eclipse 90i
fluorescent microscope. Alternatively, immunostained samples were incubated in DAPI solution and
imaged using Operetta High-Content Imaging System (Perkin Elmer, UK). Quantitative analysis of
immunofluorescence was performed using the ImageJ software (for images captured by Nikon 90i
microscope) or the Harmony Image Analysis system (for images captured by Operetta). For ImageJ,
immunostaining was quantified by determining the area of intensity of particular antibody fluorescence
over the area covered by DAPI fluorescence for each image. Immunofluorescent quantification of
samples for particular antibodies were then normalised to their respective day0 samples. For images
processed by Harmony Software, total fluorescence was calculated and averaged from 9 randomly
selected fields of view per well. All quantifications were analysed above the negative threshold set
calculated from negative control fluorescence.
2.4.Reverse Transcriptase PCR (RT-PCR) and Quantitative PCR (qPCR)
Cells were processed using TRI Reagent (Sigma-Aldrich) and total RNA extracted using RNA Clean
and Concentrator (Zymo Research) following the manufacturer’s protocols. DNAse 1 treatment was
applied and reverse transcription (RT) was performed using 1µg RNA with the Superscript 3 RT
enzyme kit, following manufacturer’s protocol. PCR was performed using the Platinum Taq DNA
polymerase kit and the following primers: Clathrin6k (F: 5’-GACAGTGCCATCATGAATCC-3’, R:
5’-TTTGTGCTTCTGGAGGAAAGAA-3’), Nestin (F: 5’-AGAGTCAGATCGCTCAGATCC-3’, R:
5’-GCAGAGTCCTGTATGTAGCCAC-3’), Sox2 (F: 5’-GGCGGCAACCAGAAGAACAG-3’, R: 5’-
GCTTGGCCTCGTCGATGAAC-3’), GFAP (F: 5’-CTCAATGCTGGCTTCAAGGAG-3’, R: 5’-
GGATCTCCTCCTCCAGCGA-3’) and βIII-tub (F: 5’-GGCCTCCTCTCACAAGTATGT-3’, R: 5’-
CAGGGAATCGAAGGGAGGTG-3’). Tubes containing no RNA and no enzyme controls were used
in parallel reactions to confirm the absence of contamination. ImageJ software was used to calculate
band intensities from gel and normalise to Clathrin6k (housekeeping gene) to provide semi-
quantification of gene expression. For qPCR, Power SYBR Green PCR Master Mix (Applied
Biosystems) was used. Gene expression was normalised against expression of Clathrin6k and calculated
using 2-ΔΔCt. The following primers were used: Clathrin6k (F: 5’-AGATTCTGCCCATTCGCTTTC-
3’, R: 5’-TCAGTGCAATCACTTTGCTGG-3’), Nestin (F: 5’-AGAGTCAGATCGCTCAGATCC-3’,
R: 5’-GCAGAGTCCTGTATGTAGCCAC-3’), Sox2 (same as mentioned above for RT-PCR), βIII-tub 
(F: 5’-GCGCCTTTGGACACCTATTCA-3’, R: 5’-GCCCTCCGTATAGTGCCCT-3’), GFAP (F: 5’-
GAGGAGTGGTATCGGTCTAAGTTTG-3’, R: 5’-GCCGCTCTAGGGACTCGTT-3’). Primers were
validated using mouse brain tissue as positive control, and mouse liver tissue as negative control. Mean
gene expression (2-ΔΔCt) was calculated between two independent experiments with three replicates 
and graphed with standard deviation (SD).
2.5.Metabolic activity assay
Presto Blue (PB) kit was used to analyse the metabolic activity of differentiating cells according to
manufacturer’s instructions. NSCs and C17.2 cells were seeded at 50,000 and 15,000 cells per well in
24-well plates, or 5000 and 1000 cells per well in 96 well plates, respectively. To normalise presto blue
fluorescence to cell numbers, cell counts were performed with ImageJ software using 3 randomly
selected regions on brightfield images for each of the 3 replicate wells analysed per condition. DNA
quantitation was carried out using the PicoGreen dsDNA assay (according to manufacturer’s protocol).
To determine the change in cell number on day2 and day4 FAS-treated and untreated samples, all cell
count values for treated samples were normalised to the cell count of day0 untreated samples. To
determine the change in metabolic activity on day2 and day4 FAS-treated and untreated samples, all
cell count-normalised PB values of treated samples were normalised to the metabolic activity of day0
untreated samples.
2.6.Cell motility Analysis
Cells were cultured in 96-well plates in biological triplicates and live imaging was performed using the
Operetta High-Content Imaging system with Harmony software. Live images were taken every 3
seconds for 2 hours and 45 minutes from one field of view in each well in brightfield and digital phase
contrast modes to enable segmentation and tracking of cells. The building blocks for analysis were as
follows: Input Image - Filter Image – Find Cells – Track Objects – Calculate Kinetic Properties –
Calculate Properties – Calculate Track Properties – Define Results. Digital phase contrast images were
used for tracking analysis and filtering using the sliding parabola option under ‘Filter Image’ block. The
‘Track Properties’ module was used to determine ‘Accumulated Distance’ (normalised to track count),
‘Start/End Type’, ‘Number of Time-points’, ‘Displacement’, and ‘Speed’ parameters of the tracked
cells. The percentage of cells tracked from ‘BEGIN’ to ‘END’ (B-E type) was defined as cells that
could be tracked throughout all timepoints without division/fusion events or any imaging hindrance
(cosmos/border). The percentage of cells tracked from ‘SPLIT’ to ‘SPLIT’ (S-S type) was defined as
actively dividing cells undergoing division at least twice while being tracked. A supplementary figure
explains the cell track types graphically (Supplementary Fig1). The accumulated distance (normalised
to track count) of B-E type tracks was used to determine changes in cell migration.
2.7.Statistical Analysis
All experiments were run in triplicates using separate cultures, with at least three internal repeats. Mean
and SD were analysed using either GraphPad Prism or Microsoft Excel. One way ANOVA with tukey’s
multiple comparison test was run to determine the statistical significance for all analysis unless
otherwise specified. Statistical significance level was set for *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001. Complete statistical data sets for all the experiments are included in a
Supplementary excel sheet (Supplementary sheet.1).
3. Results
3.1.Fasudil alters the metabolic activity and morphology of postnatal NSCs
The effect of fasudil treatment on postnatal NSCs was first analysed through metabolic activity
measured of cultures over 4 days as an indication of cell health (Fig.1A). C17.2 cells were used as a
positive control for FAS mediated neural differentiation according to a recently published study (Chen,
et al., 2015). 100µM FAS was seen to increase the metabolic activity of NSCs and C17.2 (Fig.1A). In
NSCs, FAS addition produced a significant and sustained increase in metabolic activity at both time
points (Fig.1A), while in C17.2 samples FAS treatment only showed a significant metabolic increase
only on day2 (Fig.1B).
In addition, effects on cell morphology were observed upon treatment (Fig.1). Brightfield images of
FAS-treated samples at day2 and day4 showed cytoskeletal changes with increased neurite outgrowth
in both NSCs and C17.2 cells, compared to day0 controls (Fig.1C). Total neurite length increased
significantly from day2 to day4 of FAS treatment for both cell types, and this increase was more
pronounced in C17.2 cells (Fig.1D). We noticed that NSCs showed smooth radial-like elongated neural
outgrowth with less or no branching compared to C17.2 cells (Fig.1C). To further investigate whether
the radial-like unbranched neural extensions observed in FAS-treated NSCs were of neuronal origin,
βIII-tubulin immunostaining was used. A supplementary figure contains information that revealed low 
βIII-tubulin expression in FAS-treated NSCs compared to C17.2 cells (Supplementary Fig.2). βIII-
tubulin expression showed a moderate increase in NSC neurite outgrowth by day4 (Supplementary
Fig.2A-B), suggesting the majority of NSCs after fasudil treatment did not produce neuronal-like
outgrowth but rather radial-like projections. By contrast, C17.2 showed stronger βIII-tubulin 
immunoreactivity with significant increase on day2 and day4 with FAS medium (Supplementary
Fig.2C-D).
3.2.Fasudil increases the expression of GFAP in postnatal NSCs
To further investigate changes observed in vitro in response to FAS-based medium, expression of NSC
markers Nestin and Sox2, glial marker GFAP, and neuronal marker βIII-Tubulin were analysed over 
the 4-day FAS treatment by immunostaining (Fig.2). Undifferentiated day0 postnatal NSCs showed
moderate Nestin and strong Sox2 signal, and were rare of GFAP or βIII-Tubulin expression (Fig.2A). 
Upon FAS-treatment, there was a striking loss of nestin signal, and a significant increase in Sox2
detection in day2 and day4 (all compared to day0 control) (Fig.2B). FAS-treated NSCs also displayed
significantly higher levels of GFAP expression on day2 and day4 compared to untreated control
(Fig.2B), while βIII-Tubulin signal, which was generally low, was reduced on day2 but significantly 
increased by day4 FAS-treatment. Taken together these results hinted that fasudil promoted gliogenesis
of NSCs by increasing the expression of GFAP and Sox2 (markers of proliferating NSCs and reactive
astrocytes) with concomitant reduction in Nestin and low βIII-Tubulin expression (markers of neuronal 
progenitors and early neural lineage, respectively).
Supplementary figure 3 shows the diverse effect of fasudil on C17.2 cells while supplementary figures
4 and 5 show RT-PCR results of tested neural markers and immunohistochemistry of overgrown
cultures respectively, complementing the gliogenic effect of fasudil on primary NSCs (Supplementary
Fig.3-5). In contrast to NSCs, fasudil treatment of C17.2 cells promoted the appearance of βIII-Tubulin-
positive cells (Supplementary Fig.3). Nestin signal was low in these cells but showed a significant
increase at day2 and day4 (Supplementary Fig.3B). This was accompanied by a moderate decrease in
Sox2 detection on day4 (Supplementary Fig.3B). GFAP expression was observed to be weak
throughout the treatment course. This suggests that fasudil promoted neuronal rather than glial lineage
differentiation in C17.2 cells.
RT-PCR performed to complement the immunodetection data confirmed the trends observed.
Accordingly, FAS-treated NSCs showed significant increases in sox2 and GFAP mRNA
(Supplementary Fig.4A-B) while Fas treated C17.2 showed a moderate decrease in sox2 and a
significant increase in βIII-tubulin (Supplementary Fig.4C-D).
We then compared the GFAP and βIII-Tubulin expression of day2 and day4 undifferentiated controls 
with FAS-treated NSCs and C17.2 cells (Supplementary Fig.5). Day2 FAS-treated NSCs showed higher
levels of GFAP signal compared to all untreated controls, while βIII-Tubulin was always detected at 
low levels (Supplementary Fig.5A-B). FAS-treated C17.2 showed very low levels of GFAP when
compared to untreated controls in contrast to βIII-Tubulin expression which showed high level signals 
at both FAS-treated as well as overgrown cultures (Supplementary Fig.5C-D). This shows that FAS-
treated samples differentiated in a unique manner different from that of spontaneous differentiation of
overgrown cultures in vitro.
3.3.Fasudil medium promoted radial interkinetic nuclear-like migration of
postnatal NSCs
In order to further analyse the phenotypic changes in NSCs treated with FAS-based medium, the
dynamics and migratory properties of the cells in culture were monitored by time-lapse microscopy. In
the mammalian brain, migrating NSCs are known to express GFAP and show radial-like morphology
(Malatesta, et al., 2008, Doetsch, et al., 1999, Kulikova, et al., 2011, Del Bene, 2011, Spear, et al.,
2012). Radial glia populations display INM (interkinetic nuclear movement), a distinct migration
pattern of the cell body along the radial-bidirectional cytoplasmic elongation, between the basal and
apical layer of ventricular zone (Spear, et al., 2012, Spear, et al., 2012).
When postnatal NSC cultures were monitored under FAS-based treatment, NSCs were observed to form
denser colonies and exhibited a radial-like migratory pattern suggestive of INM by day2 (Fig.3A).
Notably, there was a significant increase in trackable migratory cells (B-E type) by day4 (Fig.3B).
Supplementary video files show the radial-like movement of NSCs after FAS-treatment
(Supplementary vid.1-2). C17.2 cells showed a significant increase in trackable migratory cells both
day2 and day4, however most C17.2 cells showed a tangential migratory pattern on day2 of FAS
treatment (Fig.3A), displaying a ‘crawling’ behavior with short extentions. Additional video files show
the migrational behaviour by C17.2 cells (Supplementary vid.3). The proportion of cells undergoing
division (S-S type) significantly decreased in all FAS-medium samples compared to their day0
counterparts (Fig.3C), indicating FAS medium reduced the percentage of dividing cells or delayed the
cell division. This suggested that, exposure to FAS medium promoted a more radial-like migratory
phentype in postnatal NSCs, different from the predominantly tangential-like migratory phenotype
observed in treated C17.2 cells.
Finally, the total accumulated distance travelled by the non-dividing migratory cells in NSCs under
FAS medium was found to rise sharply compared to day0 control (Fig.3D), while for C17.2 cells, the
distance travelled under FAS medium was significantly lower than its day0 control (Fig.3D).
3.4.Fasudil-based differentiation compared to standard retinoid-based
differentiation
Adult NSCs are more restricted in terms of differentiation and migration than embryonic and early
postnatal NSCs (Obernier, et al., 2014). In order to determine how FAS treatment may affect adult
NSCs in culture and to compare its efficiency to that of conventional neuronal differentiating protocols
involving a retinoic acid analogue (RET), adult NSCs were treated in vitro with both FAS-based and
RET-based media for 10 days and monitored for metabolic and differentiation responses (Fig.4). Both
differentiation conditions were associated with rapid changes in cell morphology. By day10, NSCs in
RET medium showed mature neuronal morphologies with branched dendrites while NSCs in FAS
medium showed flat morphological properties with less branching (Fig.4A). There was no significant
difference in cellular metabolic activity between the FAS-based and the RET-based conditions at day2
and day10 (Fig.4B). Also, there was no significant reduction in metabolic activity in both FAS- and
RET- differentiation compared to day0 undifferentiated controls (Fig.4B).
Based on these observations, NSC marker analysis was performed to evaluate potential phenotypic
differences under the two differentiation regimes on day10 in vitro. A supplementary figure contains
the immunohistochemistry results for day2 of NSC differentiation (Supplementary Fig.6). Analysis of
NSC marker expression indicated that both protocols equally reduced the expression of Nestin at day10
(Fig.5A-B). RET medium produced a marked reduction of Sox2 expression by day10, while FAS
medium increased the expression of Sox2 on both day2 (Supplementary Fig.6A-B) and day10 (Fig. 5C-
D).
3.5.Divergent differentiation responses of adult NSC under FAS- and RET-
based conditions
Further analysis of lineage markers GFAP, βIII-Tubulin, S100b and DCX immunodetection was carried 
out to refine the phenotypic differences between the two treated NSC populations (Fig.6 and
Supplementary Fig.7A-B). While GFAP expression increased in both FAS and RET treatments, cells
under FAS medium displayed significantly higher expression by day10, with an elongated radial-like
morphology that was not observed in cells grown in RET medium (Fig.6A-B). Expression of the
neuronal marker βIII-Tubulin showed significant reduction in FAS medium, in contrast to the RET 
condition where multiple βIII-Tubulin positive neurons were observed (Fig.6A-B). Adult NSCs were 
further stained for S100b and DCX, markers for mature astrocytes and migrating neuroblasts,
respectively. While S100b expression was increased to comparable levels in both treatments, expression
of the neuronal marker DCX was only detected in RET medium (Fig.6A-B). qPCR analysis of these
markers at day10 (Fig.7) confirmed transcriptional changes for nestin, sox2, GFAP and βIII-tubulin
during FAS- and RET-based differentiation in line with the protein detection results, emphasizing the
divergent effect of these 2 treatments on sox2 and βIII-tubulin expression in NSCs. A supplementary
figure contains the immunohistochemistry and qPCR results for day2 of NSC differentiation
(Supplementary Fig.7).
4. Discussion
Fasudil is a ROCK inhibitor that has been shown to alleviate symptoms from a range of CNS disorders
(Chen, et al., 2013). Fasudil has been reported to improve stroke protection and blood flow after cerebral
ischaemia by increasing NO (nitric oxide) production and eNOS (endothelium-derived NO synthase)
expression (Rikitake, et al., 2005). In experimental autoimmune encephalomyelitis, fasudil has been
shown to delay the onset and severity of the disease by shifting microglia to an anti-inflammatory M2
phenotype that promotes tissue repair (Hou, et al., 2012). Moreover, studies have suggested that fasudil
can protect neurons and mobilize NSCs in in vitro ischaemic models by activating astrocyte secretion
of granulocyte-colony stimulating factor (G-CSF) and inhibiting glutamate induced neurotoxicity
(Ding, et al., 2010, Huang, et al., 2009, Yamashita, et al., 2007). Recently, it has been shown that fasudil
can mobilize endogenous NSCs in vivo and differentiate the C17.2 neural progenitor cell line in vitro
(Ding, et al., 2010, Chen, et al., 2015). Taken together, these studies suggested a role for fasudil in NSC
response and neurogenesis.
The use of fasudil has been reported in a variety of established neural and tumour cell lines at different
concentrations (Compagnucci, et al., 2016, Ding, et al., 2010, Chen, et al., 2015, Huang, et al., 2009,
Yamashita, et al., 2007, Tonges, et al., 2012, Tatenhorst, et al., 2016, Tilson, et al., 2015, Roloff, et al.,
2015, Takata, et al., 2013, Deng, et al., 2010, Lingor, et al., 2007). Recently, C17.2 cerebellar progenitor
cell line was used to study the differentiation effect of fasudil (Chen, et al., 2015). It was shown that the
differentiation was most rapid when a concentration of 100µM FAS was used, which resulted in the
production of neuronal cells expressing DCX (Chen, et al., 2015). Using the same concentration, we
showed that fasudil can differentiate C17.2 cells into βIII-tubulin neuronal cells, thereby confirming its 
effect. Interestingly, the differentiation effect of fasudil on primary NSCs had not so far been
investigated. A previous study investigating the inhibitory effect of Rho-kinase on an in vitro model of
Parkinson’s disease reported 100µM FAS to be toxic to primary midbrain neurons by reducing their
cell number (Tonges, et al., 2012), suggesting primary neural cells may be sensitive to this concentration
of fasudil. Here however, we did not observe significant signs of reduced viability or impaired metabolic
activity, indicating the dose of 100µM FAS did not compromise the integrity of primary NSC cultures.
Fasudil treatment was observed to push the primary NSCs toward a gliogenic phenotype with radial-
like properties. Radial glial NSCs present during development and radial glia-like NSCs present in the
adult mammalian brain have shown potential to form neurons in vivo that integrate within the
surrounding brain tissue and provide functional support during development, adult neurogenesis and
tissue damage (Bignami, et al., 1974, Doetsch, et al., 1999, Campbell, et al., 2002, Hutton, et al., 2011,
Götz, et al., 2015, Faiz, et al., 2015). Upon proliferation and prior to differentiation, these cells are
reported to express the markers GFAP and Sox2 (Bignami, et al., 1974, Doetsch, et al., 1999, Campbell,
et al., 2002, Hutton, et al., 2011, Götz, et al., 2015). Here, we show that the differentiation of primary
NSCs in the presence of fasudil lead to a loss of Nestin expression and an increase in Sox2 and GFAP
expression in postnatal and adult NSCs in vitro. NSCs in vivo have the ability to migrate during CNS
development or in the adult brain in response to injury. When monitoring the migratory pattern of
primary postnatal NSCs, an increase in migratory behaviour was observed in response to FAS medium.
At the early stage of treatment, postnatal NSCs exhibited INM, with the characteristic movement of cell
soma along radial extensions, a phenotype associated with radial glia known to modulate various stages
of neural development including epithelial remodelling, maintenance of epithelial structure and
polarity, and neural proliferation and differentiation (Spear, et al., 2012, Spear, et al., 2012, Glaser, et
al., 2005). FAS-treatment thus induced NSCs to display gene expression and migratory characteristics
of radial-glial progenitors in vitro, and promoted a gliogenic phenotype. This protocol produced
minimal neurogenic response, indicating the potential of fasudil as a pro-neuroglial agent. Protein and
transcript detection showed rare expression of neuronal markers upon treatment, in contrast to the
retinoid-based neuronal differentiation protocol, which induced the expression of βIII-tubulin and DCX 
in culture.
We observed an increase of Sox2 expression by day10 of FAS-treatment, which contrasted with the
response to RET-treatment. Sox2 plays a vital role in NSC proliferation and regulation (Hutton, et al.,
2011, Cimadamore, et al., 2013, Episkopou, 2005), and has been reported to inhibit neuronal
differentiation in the mouse neocortex, unless the Notch pathway is blocked (Bani-Yaghoub, et al.,
2006). A recent study has shown that overexpression of Sox2 reduced the number of MAP2 positive
neurons in human pluripotent NT2/D1 cells in vitro (Klajn, et al., 2014), while astrocytes retained Sox2
expression along with GFAP. It is thus possible to speculate that fasudil may promote gliogenesis in
NSCs by increasing Sox2 expression. Recently, fasudil has been suggested to be involved in modulating
major NSC signalling pathways including Notch and NF-kB (Chen, et al., 2015, Okamoto, et al., 2010).
Notch signalling acts as a molecular switch in regulating neural stem cell (NSC) lineage determination
in vivo and in vitro, by promoting gliogenesis, self-renewal of NSCs, and inhibiting neuronal
differentiation (Zhou, et al., 2010). Fasudil has also been known to modulate NFκB by inhibiting IL-1–
induced activation of NFκB in a rat model of rheumatoid arthritis (Okamoto, et al., 2010, Sato, et al., 
1998). In NSCs, inhibition of NF-kB has been shown to increase expression of NSC markers Nestin
and Sox2 while inhibiting neuronal differentiation in vitro (Zhang, et al., 2012). It will thus be of interest
to determine whether fasudil’s effect on Sox2 expression in primary NSCs may thus be mediated
through its effects on the Notch and/or NFκB pathways. 
5. Conclusion
The present study explored the effects of fasudil on NSC cultures derived from mouse SVZ. Fasudil
was observed to promote neural outgrowth of primary neural stem cells. Immunodetection and RT-PCR
have provided evidence that fasudil treatment promotes enhanced gliogenesis of postnatal NSCs, and
real-time imaging showed that fasudil treatment promotes radial-like inter-kinetic nuclear movement in
postnatal NSCs. A similar effect was observed in adult NSCs, as fasudil promoted gliogenesis of adult
NSCs with increase in Sox2 expression and absence of neuronal markers βIII-tubulin and DCX. These 
results provide the first evidence that fasudil can be used for the treatment of primary NSCs in culture
with no toxicity, and can promote differentiation towards a gliogenic phenotype, thus contributing to
the development of in vitro models of neural differentiation.
This study shows that fasudil treatment applied to primary NSCs provides an efficient model to analyse
the key aspects of in vivo gliogenesis. In addition to radial glia, reactive astrocytes in the adult brain
also express GFAP and Sox2 and show proliferative and migratory response towards injury (Götz, et
al., 2015, Buffo, et al., 2008). Here we report that fasudil-treated primary NSCs share the expression
and morphological patterns of radial as well as reactive gliosis, two fundamental aspects of in vivo
gliogenesis. GFAP and S100b detection highlighted the gliogenic differentiation of NSCs, and future
characterisation of this newly identified FAS-mediated response will help determine whether fasudil
can promote the appearance of specific glial subtypes such as oligodendrocytes.
Fasudil-treated NSCs can be used as a model to study INM of NSCs in vitro, providing a rapid and
efficient procedure compared to tissue slice culture and in vivo studies (Kulikova, et al., 2011, Tsai, et
al., 2010, Marin, et al., 2010). Future applications could include the molecular characterisation of INM
processes by combining this method with the recently published cell cycle staging protocol using high-
content screening (Del Bene, 2011, Roukos, et al., 2015, Cecchini, et al., 2012).
Our results also suggest that fasudil’s target, the Rho/ROCK cascade, could be an important NSC
regulatory pathway. Furthermore, fasudil has also been suggested to inhibit other functional kinases
including protein kinase N1 (PKN1), protein kinase C (PKC), cyclic nucleotide dependant protein
kinases (PKA and PKG) and Ca2+/calmodulin dependant myosin light chain kinase (MLCK) in a
concentration dependant manner, resulting in off-target effects with respect to ROCK inhibition (Asano,
et al., 1989, Fajardo, et al., 2014, Scott, 1991, Dugan, et al., 1999). It will therefore be necessary to
investigate to what extent ROCK inhibition might be the main mechanism for the fasudil-mediated
gliogenic differentiation observed in NSCs, in order to further exploit this pharmacological pathway
and its potential to regulate and control stem cell populations for CNS repair strategies.
Acknowledgements
We are grateful to Katarzyna Lis-Slimak (School of Medicine, U. of Nottingham) for her expert help
with the Operetta High-Content Imaging system. We thank Rebecca Trueman (School of Life Sciences,
U. of Nottingham), Anaid Lugo-Leija and Nigel De Melo (School of Medicine, U. of Nottingham), and
Inchirah Adala (School of Pharmacy, U. of Nottingham) for their invaluable comments. A kind donation
from R. Jones in the memory of A. Stacey is gratefully acknowledged.
6. References
M. Chen, A. Liu, Y. Ouyang, Y. Huang, X. Chao, R. Pi, Fasudil and its analogs: a new powerful
weapon in the long war against central nervous system disorders?, Expert opinion on
investigational drugs, 22 (2013) 537-550.
T. Nakamura, T. Matsui, A. Hosono, A. Okano, N. Fujisawa, T. Tsuchiya, M. Indo, Y. Suzuki,
S. Oya, H.S. Chang, Beneficial effect of selective intra-arterial infusion of fasudil
hydrochloride as a treatment of symptomatic vasospasm following SAH, Acta
neurochirurgica. Supplement, 115 (2013) 81-85.
S. Satoh, M. Takayasu, K. Kawasaki, I. Ikegaki, A. Hitomi, K. Yano, M. Shibuya, T. Asano,
Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid
hemorrhage, Journal of pharmacological sciences, 118 (2012) 92-98.
M. Hara, M. Takayasu, K. Watanabe, A. Noda, T. Takagi, Y. Suzuki, J. Yoshida, Protein kinase
inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord
injury in rats, Journal of Neurosurgery: Spine, 93 (2000) 94-101.
H. Baba, Y. Tanoue, T. Maeda, M. Kobayashi, S. Oda, R. Tominaga, Protective effects of cold
spinoplegia with fasudil against ischemic spinal cord injury in rabbits, Journal of
vascular surgery, 51 (2010) 445-452.
D. Impellizzeri, E. Mazzon, I. Paterniti, E. Esposito, S. Cuzzocrea, Effect of fasudil, a selective
inhibitor of Rho kinase activity, in the secondary injury associated with the
experimental model of spinal cord trauma, Journal of Pharmacology and Experimental
Therapeutics, 343 (2012) 21-33.
Q.M. Wang, T.J. Stalker, Y. Gong, Y. Rikitake, R. Scalia, J.K. Liao, Inhibition of Rho-kinase
attenuates endothelial–leukocyte interaction during ischemia–reperfusion injury,
Vascular Medicine, 17 (2012) 379-385.
B.K. Mueller, H. Mack, N. Teusch, Rho kinase, a promising drug target for neurological
disorders, Nature reviews. Drug discovery, 4 (2005) 387.
M. Shibuya, Y. Suzuki, K. Sugita, I. Saito, T. Sasaki, K. Takakura, I. Nagata, H. Kikuchi, T.
Takemae, H. Hidaka, Effect of AT877 on cerebral vasospasm after aneurysmal
subarachnoid hemorrhage: results of a prospective placebo-controlled double-blind
trial, Journal of neurosurgery, 76 (1992) 571-577.
B. Villar-Cheda, A. Dominguez-Meijide, B. Joglar, A.I. Rodriguez-Perez, M.J. Guerra, J.L.
Labandeira-Garcia, Involvement of microglial RhoA/Rho-kinase pathway activation in
the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors,
Neurobiology of disease, 47 (2012) 268-279.
J.M. Boyce-Rustay, G.H. Simler, S. McGaraughty, K.L. Chu, E.J. Wensink, A. Vasudevan, P.
Honore, Characterization of Fasudil in preclinical models of pain, The Journal of Pain,
11 (2010) 941-949.
S. Inan, K. Büyükafşar, Antiepileptic effects of two Rho kinase inhibitors, Y 27632 and
fasudil, in mice, British journal of pharmacology, 155 (2008) 44-51.
X.-f. Jia, F. Ye, Y.-b. Wang, D.-x. Feng, ROCK inhibition enhances neurite outgrowth in neural
stem cells by upregulating YAP expression in vitro, Neural Regeneration Research, 11
(2016) 983.
H. Gu, S.P. Yu, C.-A. Gutekunst, R.E. Gross, L. Wei, Inhibition of the Rho signaling pathway
improves neurite outgrowth and neuronal differentiation of mouse neural stem cells, Int
J Physiol Pathophysiol Pharmacol, 5 (2013) 11-20.
J. Liu, H.-y. Gao, X.-f. Wang, The role of the Rho/ROCK signaling pathway in inhibiting
axonal regeneration in the central nervous system, Neural Regeneration Research, 10
(2015) 1892-1896.
C. Compagnucci, S. Barresi, S. Petrini, P. Billuart, G. Piccini, P. Chiurazzi, P. Alfieri, E.
Bertini, G. Zanni, Rho Kinase Inhibition Is Essential During In Vitro Neurogenesis and
Promotes Phenotypic Rescue of Human Induced Pluripotent Stem Cell-Derived
Neurons With Oligophrenin-1 Loss of Function, Stem cells translational medicine, 5
(2016) 860-869.
H. Ying, S.L. Biroc, W.W. Li, B. Alicke, J.A. Xuan, R. Pagila, Y. Ohashi, T. Okada, Y.
Kamata, H. Dinter, The Rho kinase inhibitor fasudil inhibits tumor progression in
human and rat tumor models, Molecular cancer therapeutics, 5 (2006) 2158-2164.
J. Ding, Q.Y. Li, J.Z. Yu, X. Wang, C.H. Sun, C.Z. Lu, B.G. Xiao, Fasudil, a Rho kinase
inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation
injury in mice, Molecular and cellular neurosciences, 43 (2010) 201-208.
S. Chen, M. Luo, Y. Zhao, Y. Zhang, M. He, W. Cai, A. Liu, Fasudil Stimulates Neurite
Outgrowth and Promotes Differentiation in C17.2 Neural Stem Cells by Modulating
Notch Signalling but not Autophagy, Cellular physiology and biochemistry :
international journal of experimental cellular physiology, biochemistry, and
pharmacology, 36 (2015) 531-541.
P. Malatesta, I. Appolloni, F. Calzolari, Radial glia and neural stem cells, Cell and tissue
research, 331 (2008) 165-178.
F. Doetsch, I. Caille, D.A. Lim, J.M. Garcia-Verdugo, A. Alvarez-Buylla, Subventricular zone
astrocytes are neural stem cells in the adult mammalian brain, Cell, 97 (1999) 703-716.
S. Kulikova, M. Abatis, C. Heng, V. Lelievre, Interkinetic nuclear migration, Cell Adhesion &
Migration, 5 (2011) 277-279.
F. Del Bene, Interkinetic nuclear migration: cell cycle on the move, The EMBO journal, 30
(2011) 1676-1677.
P.C. Spear, C.A. Erickson, Interkinetic nuclear migration: a mysterious process in search of a
function, Development, growth & differentiation, 54 (2012) 306-316.
P.C. Spear, C.A. Erickson, Apical movement during interkinetic nuclear migration is a two-
step process, Developmental biology, 370 (2012) 33-41.
K. Obernier, C.K. Tong, A. Alvarez-Buylla, Restricted nature of adult neural stem cells: re-
evaluation of their potential for brain repair, Frontiers in neuroscience, 8 (2014).
Y. Rikitake, H.H. Kim, Z. Huang, M. Seto, K. Yano, T. Asano, M.A. Moskowitz, J.K. Liao,
Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke
protection, Stroke, 36 (2005) 2251-2257.
S.W. Hou, C.Y. Liu, Y.H. Li, J.Z. Yu, L. Feng, Y.T. Liu, M.F. Guo, Y. Xie, J. Meng, H.F.
Zhang, B.G. Xiao, C.G. Ma, Fasudil ameliorates disease progression in experimental
autoimmune encephalomyelitis, acting possibly through antiinflammatory effect, CNS
neuroscience & therapeutics, 18 (2012) 909-917.
L. Huang, Q. Li, H. Li, Z. He, Z. Cheng, J. Chen, L. Guo, Inhibition of intracellular Ca 2+
release by a Rho-kinase inhibitor for the treatment of ischemic damage in primary
cultured rat hippocampal neurons, European journal of pharmacology, 602 (2009) 238-
244.
K. Yamashita, Y. Kotani, Y. Nakajima, M. Shimazawa, S.-i. Yoshimura, S. Nakashima, T.
Iwama, H. Hara, Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic
neuronal damage in vitro and in vivo by acting directly on neurons, Brain research,
1154 (2007) 215-224.
L. Tonges, T. Frank, L. Tatenhorst, K.A. Saal, J.C. Koch, E.M. Szego, M. Bahr, J.H.
Weishaupt, P. Lingor, Inhibition of rho kinase enhances survival of dopaminergic
neurons and attenuates axonal loss in a mouse model of Parkinson's disease, Brain : a
journal of neurology, 135 (2012) 3355-3370.
L. Tatenhorst, K. Eckermann, V. Dambeck, L. Fonseca-Ornelas, H. Walle, T. Lopes da
Fonseca, J.C. Koch, S. Becker, L. Tonges, M. Bahr, T.F. Outeiro, M. Zweckstetter, P.
Lingor, Fasudil attenuates aggregation of alpha-synuclein in models of Parkinson's
disease, Acta neuropathologica communications, 4 (2016) 39.
S.G. Tilson, E.M. Haley, U.L. Triantafillu, D.A. Dozier, C.P. Langford, G.Y. Gillespie, Y.
Kim, ROCK Inhibition Facilitates In Vitro Expansion of Glioblastoma Stem-Like
Cells, PLOS ONE, 10 (2015) e0132823.
F. Roloff, H. Scheiblich, C. Dewitz, S. Dempewolf, M. Stern, G. Bicker, Enhanced neurite
outgrowth of human model (NT2) neurons by small-molecule inhibitors of Rho/ROCK
signaling, PloS one, 10 (2015) e0118536.
M. Takata, H. Tanaka, M. Kimura, Y. Nagahara, K. Tanaka, K. Kawasaki, M. Seto, K.
Tsuruma, M. Shimazawa, H. Hara, Fasudil, a rho kinase inhibitor, limits motor neuron
loss in experimental models of amyotrophic lateral sclerosis, British journal of
pharmacology, 170 (2013) 341-351.
L. Deng, G. Li, R. Li, Q. Liu, Q. He, J. Zhang, Rho-kinase inhibitor, fasudil, suppresses
glioblastoma cell line progression in vitro and in vivo, Cancer biology & therapy, 9
(2010) 875-884.
P. Lingor, N. Teusch, K. Schwarz, R. Mueller, H. Mack, M. Bahr, B.K. Mueller, Inhibition of
Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan
in vitro and axonal regeneration in the adult optic nerve in vivo, Journal of
neurochemistry, 103 (2007) 181-189.
A. Bignami, D. Dahl, Astrocyte-specific protein and radial glia in the cerebral cortex of
newborn rat, Nature, 252 (1974) 55-56.
F. Doetsch, I. Caille, D.A. Lim, J.M. García-Verdugo, A. Alvarez-Buylla, Subventricular zone
astrocytes are neural stem cells in the adult mammalian brain, Cell, 97 (1999) 703-716.
K. Campbell, M. Gotz, Radial glia: multi-purpose cells for vertebrate brain development,
Trends in neurosciences, 25 (2002) 235-238.
S.R. Hutton, L.H. Pevny, SOX2 expression levels distinguish between neural progenitor
populations of the developing dorsal telencephalon, Developmental Biology, 352
(2011) 40-47.
M. Götz, S. Sirko, J. Beckers, M. Irmler, Reactive astrocytes as neural stem or progenitor cells:
In vivo lineage, In vitro potential, and Genome wide expression analysis, Glia, 63
(2015) 1452-1468.
M. Faiz, N. Sachewsky, S. Gascón, K.W.A. Bang, Cindi M. Morshead, A. Nagy, Adult Neural
Stem Cells from the Subventricular Zone Give Rise to Reactive Astrocytes in the
Cortex after Stroke, Cell Stem Cell, 17 (2015) 624-634.
T. Glaser, O. Brüstle, Retinoic acid induction of ES-cell-derived neurons: the radial glia
connection, Trends in neurosciences, 28 (2005) 397-400.
F. Cimadamore, A. Amador-Arjona, C. Chen, C.-T. Huang, A.V. Terskikh, SOX2–LIN28/let-
7 pathway regulates proliferation and neurogenesis in neural precursors, Proceedings
of the National Academy of Sciences, 110 (2013) E3017-E3026.
V. Episkopou, SOX2 functions in adult neural stem cells, Trends in neurosciences, 28 (2005)
219-221.
M. Bani-Yaghoub, R.G. Tremblay, J.X. Lei, D. Zhang, B. Zurakowski, J.K. Sandhu, B. Smith,
M. Ribecco-Lutkiewicz, J. Kennedy, P.R. Walker, Role of Sox2 in the development of
the mouse neocortex, Developmental biology, 295 (2006) 52-66.
A. Klajn, D. Drakulic, M. Tosic, Z. Pavkovic, M. Schwirtlich, M. Stevanovic, SOX2
overexpression affects neural differentiation of human pluripotent NT2/D1 cells,
Biochemistry (Moscow), 79 (2014) 1172-1182.
H. Okamoto, T. Yoshio, H. Kaneko, H. Yamanaka, Inhibition of NF-kappaB signaling by
fasudil as a potential therapeutic strategy for rheumatoid arthritis, Arthritis and
rheumatism, 62 (2010) 82-92.
Z.D. Zhou, U. Kumari, Z.C. Xiao, E.K. Tan, Notch as a molecular switch in neural stem cells,
IUBMB life, 62 (2010) 618-623.
T. Sato, K. Asamitsu, J.P. Yang, N. Takahashi, T. Tetsuka, A. Yoneyama, A. Kanagawa, T.
Okamoto, Inhibition of human immunodeficiency virus type 1 replication by a
bioavailable serine/threonine kinase inhibitor, fasudil hydrochloride, AIDS research
and human retroviruses, 14 (1998) 293-298.
Y. Zhang, J. Liu, S. Yao, F. Li, L. Xin, M. Lai, V. Bracchi-Ricard, H. Xu, W. Yen, W. Meng,
S. Liu, L. Yang, S. Karmally, J. Liu, H. Zhu, J. Gordon, K. Khalili, S. Srinivasan, J.R.
Bethea, X. Mo, W. Hu, Nuclear factor kappa B signaling initiates early differentiation
of neural stem cells, Stem cells (Dayton, Ohio), 30 (2012) 510-524.
A. Buffo, I. Rite, P. Tripathi, A. Lepier, D. Colak, A.P. Horn, T. Mori, M. Gotz, Origin and
progeny of reactive gliosis: A source of multipotent cells in the injured brain,
Proceedings of the National Academy of Sciences of the United States of America, 105
(2008) 3581-3586.
J.-W. Tsai, W.-N. Lian, S. Kemal, A.R. Kriegstein, R.B. Vallee, Kinesin 3 and cytoplasmic
dynein mediate interkinetic nuclear migration in neural stem cells, Nat Neurosci, 13
(2010) 1463-1471.
O. Marin, M. Valiente, X. Ge, L.H. Tsai, Guiding neuronal cell migrations, Cold Spring Harbor
perspectives in biology, 2 (2010) a001834.
V. Roukos, G. Pegoraro, T.C. Voss, T. Misteli, Cell cycle staging of individual cells by
fluorescence microscopy, Nat. Protocols, 10 (2015) 334-348.
M.J. Cecchini, M. Amiri, F.A. Dick, Analysis of cell cycle position in mammalian cells, Journal
of visualized experiments : JoVE, (2012).
T. Asano, T. Suzuki, M. Tsuchiya, S. Satoh, I. Ikegaki, M. Shibuya, Y. Suzuki, H. Hidaka,
Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the
inhibition of protein kinase, British journal of pharmacology, 98 (1989) 1091-1100.
A.M. Fajardo, G.A. Piazza, H.N. Tinsley, The role of cyclic nucleotide signaling pathways in
cancer: targets for prevention and treatment, Cancers, 6 (2014) 436-458.
J.D. Scott, Cyclic nucleotide-dependent protein kinases, Pharmacology & therapeutics, 50
(1991) 123-145.
L.L. Dugan, J.S. Kim, Y. Zhang, R.D. Bart, Y. Sun, D.M. Holtzman, D.H. Gutmann,
Differential effects of cAMP in neurons and astrocytes role of B-raf, Journal of
Biological Chemistry, 274 (1999) 25842-25848.
Figure captions
Figure 1 Change in metabolic activity and neurite outgrowth upon FAS treatment. (A-B)
Normalised metabolic activity measurements of postnatal NSCs (A) and C17.2 (B) cultures at 2 and 4
days of treatment with 100µM FAS. All sample have been normalised to day0 undifferentiated samples
(dotted line). (C-D) Changes in neurite outgrowth upon FAS treatment analysed by brightfield images
(C), with corresponding image analysis of neurite length of NSCs and C17.2 (D). Zoomed in boxes in
(C) show details at higher magnification. Arrows show the radial-like morphology of cells. Scale bar:
250µm. Statistical significance: * p<0.05
Figure 2 Marker expression analysis in postanatal NSCs exposed to fasudil. (A)
Immunofluorescence images showing the expression of Nestin (green), Sox2 (red), GFAP (green) and
βIII-tubulin (green) in undifferentiated day0 and FAS-treated postnatal NSCs at day 2and day4. DAPI 
used as nuclear counterstain (blue). (B) Corresponding signal quantitation using image analysis (dotted
line is day0). Scale bar 250µm. * p≤0.05 
Figure 3 Comparative time-lapse analysis of postnatal NSCs and C17.2 cells upon treatment with
FAS medium. (A) Morphological changes of postnatal NSCs and C17.2 cells in vitro. Example of
nucleo-kinetic locomotion of day2 treated NSCs and tangential locomotion of day 2 treated C17.2 cells.
T0, T25, T50 represent sequential time-points. Red, green and yellow markings represent the tracking
of three independent cells in the images. White arrows show the radial-like morphology of cells. The
yellow arrow shows the denser colony formed during FAS differentiation of NSCs. Scale bar 50µm.
(B) Percentage of trackable migratory cells (B-E type) in NSCs and C17.2 samples. (C) Percentage of
dividing cells (S-S type) tracked in postnatal NSCs and C17.2 samples. (D) Quantitative analysis
showing the total distance migrated by postnatal NSCs and C17.2 cells treated with FAS medium vs.
undifferentiated cells. * p<0.05
Figure 4 Morphological and metabolic response of adult NSCs during RET- and FAS-
differentiation on day2 and day10. (A) Morphological changes- arrows show the branching neurites
in RET-treated adult NSCs vs flattened radial-like outgrowth in FAS-treated adult NSCs at day10. Scale
bar 250µm. (B) Metabolic activity normalised to DNA content (dotted line is day0). * p<0.05
Figure 5 Nestin and Sox2 expression in adult NSCs under FAS- and RET-differentiation
protocols. (A) Nestin (green) and Sox2 (red) immunostaining at day0 and day10 of treatment and (B)
corresponding image quantitation analysis (dotted line is day0). DAPI used as nuclear counterstain
(blue). Scale bar 200µm. * p<0.05
Figure 6 GFAP, βIII-tubulin, s100b and DCX expression (red) in adult NSCs under FAS- and 
RET-differentiation protocols. (A) Immunofluorescence images at day0 and day10 of treatment
(arrows indicate elongated radial-like neural outgrowth in GFAP positive cells) and (B) corresponding
image quantitation analysis (dotted line is day0). DAPI used as nuclear counterstain (blue). Scale bar
200µm. * p≤0.05 
Figure 7: qPCR analysis of adult NSCs in FAS- and RET-based medium on day10 of
differentiation under FAS- and RET- differentiation protocols for Nestin, Sox2, GFAP and βIII-tub
(dotted line is day0). * p<0.05
